PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1401936
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1401936
Immunology Market Forecasts to 2030 - Global Analysis By Drug Class (Immunosuppressants, Monoclonal Antibody, Fusion Proteins, Polyclonal Antibody and Other Drug Classes), Disease Indication, Application and By Geography
According to Stratistics MRC, the Global Immunology Market is accounted for $98.93 billion in 2023 and is expected to reach $184.21 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Immunology is the branch of biomedical science that focuses on the study of the immune system - the complex network of cells, tissues, organs, and molecules that work together to defend the body against infections and other diseases. Immunology is a dynamic and rapidly evolving field with broad applications in medicine, ranging from infectious disease management to the treatment of autoimmune conditions and cancer.
According to British Society for Immunology, in 2018, around 400,000 people in U.K are suffering with rheumatoid arthritis.
Market Dynamics:
Driver:
Increasing prevalence of immunological disorders
Genetic factors and the aging global population play a significant role in the development of many immunological disorders. Exposure to certain environmental factors, such as infections, pollutants, and toxins, may trigger or exacerbate immunological disorders. These disorders foster a competitive environment within the immunology market. It results in a larger patient population seeking medical intervention. Thereby, the increasing prevalence of immunological disorders creates a multifaceted impact on the immunology market, driving demand, innovation, and investment in research and development.
Restraint:
Strict regulations
Regulations in the immunology market are designed to ensure the safety, efficacy, and quality of products related to immunological disorders. These regulations are complex and stringent regulatory processes for the approval of immunology drugs can result in delays and increased development costs. Regulatory hurdles may limit the number of new therapies entering the market. This could further hinder the development of novel immunological therapies and limit the overall innovation in the market.
Opportunity:
Advancements in biotechnology & immunotherapy
Novel strategies for treating a range of immunological illnesses are being introduced by developments in biotechnology and immunotherapy. They make it possible to create specialised treatments that target the underlying causes of immune diseases. Moreover, personalised treatment techniques are made possible by technological breakthroughs. Alongside these important developments in immunotherapy have been cell and gene treatments. Because of these advances, the immunology market is driven by the creation of personalized medical strategies, targeted medicines, and cutting-edge treatment methods.
Threat:
Competition from biosimilars
The introduction of biosimilars, which are lower-cost alternatives to biologic drugs, can pose a threat to the market. Increased competition may lead to pricing pressures and reduced market share for originator immunology drugs. Further, the development of alternative therapies, including small molecules and gene therapies, may also pose a threat to traditional immunology drugs. These emerging therapies could offer new treatment options and potentially capture market share.
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the immunology market. During the pandemic, immunology research was increased to understand the effects of covid on immunity and cope with the severe effects of the same. The success of various COVID-19 vaccines has highlighted the importance of immunology in addressing global health crises, potentially leading to increased investment and interest in immunology research. Also, the emergence of new variants of the SARS-CoV-2 virus has kept the spotlight on immunology, which influenced future developments in immunology market.
The monoclonal antibody segment is expected to be the largest during the forecast period
Themonoclonal antibody segment is estimated to have a lucrative growth, due to the clinical efficiency of the procedure and the high prevalence of drugs. Monoclonal antibodies are proteins made in the laboratory for binding to specific targets in the body, such as antigens. They can enhance, restore, modify, or mimic the immune system's attack on unwanted cells. Their easy government approvals and relatively low levels of risk, is further pushing the segment expansion.
The rheumatoid arthritis segment is expected to have the highest CAGR during the forecast period
The rheumatoid arthritis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the growing geriatric population and rising R&D. Rheumatoid arthritis is a chronic inflammatory disorder that affects joints. Rheumatoid arthritis serves as a key driver for advancements in the immunology market by providing a specific focus on immune system deregulation, leading to the development of targeted therapies, diagnostic tools, and a deeper understanding of autoimmune diseases.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to the presence of a well-established healthcare infrastructure. The region has the high prevalence of autoimmune diseases and chronic inflammatory conditions. Numerous pharmaceutical firms are actively involved in the research and marketing of immunology medications in the fiercely competitive North American market. Pfizer, Johnson & Johnson, Amgen, AbbVie, and other significant firms are doing well in this region market. Additionally, a greater diagnosis rate among patients in the area is probably going to support the expansion of the sector.
Region with highest CAGR:
Europe is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of autoimmune disorders. The region is home for several key players such as Genmab, Arctoris, Valo Therapeutics and BioNTech. Additionally, London estimates 7% of the U.K. population, or over 4 million individuals, have at least one autoimmune disorder. The region is also making efforts to secure approvals and launch drugs targeting autoimmune conditions. Thereon, the European market is driven by growing health-consciousness among consumers and boosted by the COVID-19 pandemic.
Key players in the market:
Some of the key players profiled in the Immunology Market include Novartis AG, Eli Lilly and Company, AbbVie Inc., Janssen Global Services LLC, UCB SA, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, F. Hoffmann-La Roche Limited, Astellas Pharma Inc. and Merck Sharp & Dohme Corporation.
Key Developments:
In March 2023, Eli Lilly and Company received approval from the Indian regulatory agency Directorate General of Commercial Intelligence and Statistics (DGCI). This approval allowed them to launch their drug, Copellor, for the treatment of moderate-to-severe plaque psoriasis and also for psoriatic arthritis.
In March 2022, Pfizer Inc. enhanced its product offering by acquiring Arena Pharmaceuticals, a company dedicated to developing cutting-edge therapies for various immuno-inflammatory diseases.
Drug Classes Covered:
- Immunosuppressants
- Monoclonal Antibody
- Fusion Proteins
- Polyclonal Antibody
- Other Drug Classes
Disease Indications Covered:
- Plaque Psoriasis
- Rheumatoid Arthritis
- Prophylaxis of Organ Rejection
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Other Disease Indications
Applications Covered:
- Hospital
- Clinics
- Cancer Research Centers & Institutions
- Other Applications
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Immunology Market, By Drug Class
- 5.1 Introduction
- 5.2 Immunosuppressants
- 5.3 Monoclonal Antibody
- 5.4 Fusion Proteins
- 5.5 Polyclonal Antibody
- 5.6 Other Drug Classes
6 Global Immunology Market, By Disease Indication
- 6.1 Introduction
- 6.2 Plaque Psoriasis
- 6.3 Rheumatoid Arthritis
- 6.4 Prophylaxis of Organ Rejection
- 6.5 Psoriatic Arthritis
- 6.6 Ankylosing Spondylitis
- 6.7 Inflammatory Bowel Disease
- 6.8 Other Disease Indications
7 Global Immunology Market, By Application
- 7.1 Introduction
- 7.2 Hospital
- 7.3 Clinics
- 7.4 Cancer Research Centers & Institutions
- 7.5 Other Applications
8 Global Immunology Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 Novartis AG
- 10.2 Eli Lilly and Company
- 10.3 AbbVie Inc.
- 10.4 Janssen Global Services LLC
- 10.5 UCB SA
- 10.6 Amgen Inc.
- 10.7 Pfizer Inc.
- 10.8 Bristol-Myers Squibb Company
- 10.9 Aurobindo Pharma
- 10.10 F. Hoffmann-La Roche Limited
- 10.11 Astellas Pharma Inc.
- 10.12 Merck Sharp & Dohme Corporation
List of Tables
- Table 1 Global Immunology Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
- Table 3 Global Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
- Table 4 Global Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
- Table 5 Global Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
- Table 6 Global Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
- Table 7 Global Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
- Table 8 Global Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
- Table 9 Global Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
- Table 10 Global Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
- Table 11 Global Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
- Table 12 Global Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
- Table 13 Global Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
- Table 14 Global Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
- Table 15 Global Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
- Table 16 Global Immunology Market Outlook, By Application (2021-2030) ($MN)
- Table 17 Global Immunology Market Outlook, By Hospital (2021-2030) ($MN)
- Table 18 Global Immunology Market Outlook, By Clinics (2021-2030) ($MN)
- Table 19 Global Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
- Table 20 Global Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 21 North America Immunology Market Outlook, By Country (2021-2030) ($MN)
- Table 22 North America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
- Table 23 North America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
- Table 24 North America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
- Table 25 North America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
- Table 26 North America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
- Table 27 North America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
- Table 28 North America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
- Table 29 North America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
- Table 30 North America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
- Table 31 North America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
- Table 32 North America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
- Table 33 North America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
- Table 34 North America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
- Table 35 North America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
- Table 36 North America Immunology Market Outlook, By Application (2021-2030) ($MN)
- Table 37 North America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
- Table 38 North America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
- Table 39 North America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
- Table 40 North America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 41 Europe Immunology Market Outlook, By Country (2021-2030) ($MN)
- Table 42 Europe Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
- Table 43 Europe Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
- Table 44 Europe Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
- Table 45 Europe Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
- Table 46 Europe Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
- Table 47 Europe Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
- Table 48 Europe Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
- Table 49 Europe Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
- Table 50 Europe Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
- Table 51 Europe Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
- Table 52 Europe Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
- Table 53 Europe Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
- Table 54 Europe Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
- Table 55 Europe Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
- Table 56 Europe Immunology Market Outlook, By Application (2021-2030) ($MN)
- Table 57 Europe Immunology Market Outlook, By Hospital (2021-2030) ($MN)
- Table 58 Europe Immunology Market Outlook, By Clinics (2021-2030) ($MN)
- Table 59 Europe Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
- Table 60 Europe Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 61 Asia Pacific Immunology Market Outlook, By Country (2021-2030) ($MN)
- Table 62 Asia Pacific Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
- Table 63 Asia Pacific Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
- Table 64 Asia Pacific Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
- Table 65 Asia Pacific Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
- Table 66 Asia Pacific Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
- Table 67 Asia Pacific Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
- Table 68 Asia Pacific Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
- Table 69 Asia Pacific Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
- Table 70 Asia Pacific Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
- Table 71 Asia Pacific Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
- Table 72 Asia Pacific Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
- Table 73 Asia Pacific Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
- Table 74 Asia Pacific Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
- Table 75 Asia Pacific Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
- Table 76 Asia Pacific Immunology Market Outlook, By Application (2021-2030) ($MN)
- Table 77 Asia Pacific Immunology Market Outlook, By Hospital (2021-2030) ($MN)
- Table 78 Asia Pacific Immunology Market Outlook, By Clinics (2021-2030) ($MN)
- Table 79 Asia Pacific Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
- Table 80 Asia Pacific Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 81 South America Immunology Market Outlook, By Country (2021-2030) ($MN)
- Table 82 South America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
- Table 83 South America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
- Table 84 South America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
- Table 85 South America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
- Table 86 South America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
- Table 87 South America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
- Table 88 South America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
- Table 89 South America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
- Table 90 South America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
- Table 91 South America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
- Table 92 South America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
- Table 93 South America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
- Table 94 South America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
- Table 95 South America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
- Table 96 South America Immunology Market Outlook, By Application (2021-2030) ($MN)
- Table 97 South America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
- Table 98 South America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
- Table 99 South America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
- Table 100 South America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 101 Middle East & Africa Immunology Market Outlook, By Country (2021-2030) ($MN)
- Table 102 Middle East & Africa Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
- Table 103 Middle East & Africa Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
- Table 104 Middle East & Africa Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
- Table 105 Middle East & Africa Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
- Table 106 Middle East & Africa Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
- Table 107 Middle East & Africa Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
- Table 108 Middle East & Africa Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
- Table 109 Middle East & Africa Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
- Table 110 Middle East & Africa Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
- Table 111 Middle East & Africa Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
- Table 112 Middle East & Africa Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
- Table 113 Middle East & Africa Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
- Table 114 Middle East & Africa Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
- Table 115 Middle East & Africa Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
- Table 116 Middle East & Africa Immunology Market Outlook, By Application (2021-2030) ($MN)
- Table 117 Middle East & Africa Immunology Market Outlook, By Hospital (2021-2030) ($MN)
- Table 118 Middle East & Africa Immunology Market Outlook, By Clinics (2021-2030) ($MN)
- Table 119 Middle East & Africa Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
- Table 120 Middle East & Africa Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
